PS
MDGL icon

Principal Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History

Principal Securities’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-71
Closed -$32.6K – 2645
2025
Q3 		$32.6K Sell
71
-5
-7% -$1.86K ﹤0.01% 2169
2025
Q2 		$23K Buy
76
+6
+9% +$1.79K ﹤0.01% 2248
2025
Q1 		$21.6K Hold
70
– – ﹤0.01% 2151
2024
Q4 		$21.6K Buy
70
+3
+4% +$844 ﹤0.01% 2147
2024
Q3 		$14.2K Sell
67
-81
-55% -$20.7K ﹤0.01% 2279
2024
Q2 		$41.5K Buy
148
+4
+3% +$952 ﹤0.01% 1706
2024
Q1 		$38.5K Buy
144
+96
+200% +$22.6K ﹤0.01% 1694
2023
Q4 		$11.1K Buy
+48
New +$8.4K ﹤0.01% 2190

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Principal Securities's MDGL Position: Q4 2025 in Review

Principal Securities sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 71 shares — an estimated $32.6K sold.

Principal Securities first reported a position in MDGL in Q4 2023 and held it in 8 quarters. The position peaked at $41.5K in Q2 2024. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Principal Securities reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 71 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $32.6K.
  • Principal Securities first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Madrigal Pharmaceuticals position peaked at $41.5K in Q2 2024.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.